The Thunderbolt device from California-based Penumbra uses modulated aspiration to detect and remove blood clots. Back in January, Boston Scientific agreed to acquire Penumbra for approximately $14.5 billion.

Researchers tracked real-world data from more than 140 patients who originally received a transcatheter heart valve from Edwards Lifesciences, Medtronic or Boston Scientific. 

The new recall impacts thousands of portable systems. A software update is now available that should resolve any issues. 

MRI-detected signs of cardiac remodeling may tell clinicians a thing or two about a patient's odds of developing certain cancers. Changes in heart muscle mass, for example, were linked to an increased risk of breast cancer. 

A vast majority of patient deaths in the first year after TAVR have nothing to do with heart health. Could care teams be doing more to identify high-risk patients? 

A failed TAVR procedure has left one family unsure about where things went wrong. 

These programs may provide benefits in some cases. In others, however, there is a concern that they could actually lead to higher costs over time.

Patients who exercise and take all prescribed medications, for instance, experience better outcomes than those who do not.

Science shows the deep relationship between cardiac, kidney and metabolism issues that may impact up to 90% of the U.S. population.  

Funds with help bring its cellular therapeutics to market in the next year.